Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
From ENZC Press release dated October 19, 2020:
The critical nature of targeting immutable sites on the Coronavirus will be the same. I note the recent news that Eli Lilly has paused its anti-Coronavirus monoclonal antibody trials. We are not privy to the underlying reasons for such pause, but this could be due to failure to target immutable sites on the virus or on the methodology for producing the monoclonal antibodies. When we recently asked Eli Lilly for the identity of the binding sites for its anti-Coronavirus monoclonal antibodies, they were unable to share that information with us. The fact is that multiple neutralizing antibodies will be necessary to control the Coronavirus, just as is the case with HIV. Our program is to produce multiple antibodies each targeting conserved, immutable sites on the virus.
What happened to Eli Lilly's Coronavirus monoclonal antibody?
On Nov. 9, 2020, based on the totality of scientific evidence available at the time, the FDA issued an EUA to Eli Lilly and Co. authorizing the emergency use of bamlanivimab alone for the treatment of mild to moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progressing to severe COVID-19 and/or hospitalization. Importantly, although the FDA is now revoking this EUA, alternative monoclonal antibody therapies remain available under EUA, including REGEN-COV (casirivimab and imdevimab, administered together), and bamlanivimab and etesevimab, administered together, for the same uses as previously authorized for bamlanivimab alone. The FDA believes that these alternative monoclonal antibody therapies remain appropriate to treat patients with COVID-19 when used in accordance with the authorized labeling based on information available at this time.
https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-revokes-emergency-use-authorization-monoclonal-antibody-bamlanivimab
Then the HAMMER came down:
The Assistant Secretary for Preparedness and Response (ASPR) and the Food and Drug Administration (FDA) within the U.S. Department of Health and Human Services are committed to ensuring timely and transparent communication regarding the COVID-19 monoclonal antibody treatments currently authorized for emergency use in certain patients with COVID-19.
Today, we are informing you that ASPR is immediately pausing all distribution of bamlanivimab and etesevimab together and etesevimab alone (to pair with existing supply of bamlanivimab at a facility for use under EUA 094) on a national basis until further notice. In addition, FDA recommends that health care providers nationwide use alternative authorized monoclonal antibody therapies, as described below, and not use bamlanivimab and etesevimab administered together at this time.
https://www.phe.gov/emergency/events/COVID19/investigation-MCM/Bamlanivimab-etesevimab/Pages/bamlanivimab-etesevimab-distribution-pause.aspx
So what is Eli Lilly up to now?
Eli Lilly has begun clinical development of an anti-SARS-CoV-2 antibody designed to work against all currently known circulating variants of concern. The action comes weeks after the FDA revoked the single use emergency authorization of Lilly’s first COVID-19 antibody due to the rise of variants.
Researchers have shown COVID-19 antibodies including Lilly’s bamlanivimab are less effective against variants of concern such as B.1.351 than the original SARS-CoV-2 virus when given as monotherapies. The research, coupled to the emergence of variants of concern as the dominant causes of COVID-19 in parts of the world, has led to reassessments of the use of antibodies as single agents.
AbCellera, which worked with Lilly on bamlanivimab, responded to variants by searching the blood of a patient who recovered from COVID-19 for an antibody that is effective against them. The result is LY-CoV1404, an antibody that binds to a conserved part of the receptor-binding domain.
https://www.fiercebiotech.com/biotech/lilly-takes-variant-busting-covid-19-antibody-into-clinic
What about the other Coronavirus monoclonal antibody from AstraZeneca?
AstraZeneca said on Tuesday a late-stage trial failed to provide evidence that its Covid-19 antibody therapy protected people who had contact with an infected person from the disease, a small setback in its efforts to find alternatives to vaccines.
The study assessed whether the therapy, a cocktail of two types of antibodies, could prevent adults who had been exposed to the virus in the past eight days from developing Covid-19 symptoms.
The therapy, AZD7442, was 33% effective in reducing the risk of people developing symptoms compared with a placebo, but that result was not statistically significant — meaning it might have been due to chance and not the therapy.
The Phase III study, which has not been peer reviewed, included 1,121 participants in the United Kingdom and the United States. The vast majority, though not all, were free of the virus at the start of the trial.
AstraZeneca also said on Tuesday it was in talks with the U.S. government on “next steps” regarding a $205 million deal to supply up to 500,000 doses of AZD7442. Swiss manufacturer Lonza was contracted to produce AZD7442.
https://www.cnbc.com/2021/06/15/astra-antibody-cocktail-fails-to-prevent-covid-19-symptoms-in-trial.html
Slow and Steady ENZC Dot the i and Cross the t your place on the Big Stage will become a REALITY!!!
The PR puts to rest ENZC being sold.
ENZC is setting itself up to be a PLAYER in the BIG PHARMA arena.
Small Pharma Driving Big Pharma Innovation
The Path to R&D Innovation Lies in the Power of Small Pharma
Visionary thought leaders such as Bernard Munos of InnoThink and the Milken Institute and Paul Stoffels, M.D., vice chairman of the executive committee and chief scientific officer, Johnson & Johnson, have been advocating for years that the blockbuster model is broken and unsustainable. They have been pushing for a change in the R&D model that will drive more transformational innovation. That day of transformation may be upon us, as small biotech and large pharma companies have started to work synergistically to create a faster, more cost-effective way to bring new treatments to market.
The short story is that small pharma brings nimbleness and a focused-approach to science that is uninhibited by the bureaucracy of large pharma, and large pharma provides the funding and the sales and marketing muscle to bring these innovative drugs to patients. This symbiotic relationship has proven to be a win-win.
This trend has been growing rapidly over the past five years within the industry’s R&D model. Gone are the guarded, years-long, high-cost searches for a blockbuster that was so common years ago for large pharma companies. Today, small pharma companies are overwhelmingly driving innovation, accounting for 63% of all new prescription drug approvals over the past five years. A report by HBM partners showcases this trend by tracking the NMEs that were originally developed by small, mid-sized, and big pharma companies. In 2009, small pharma was responsible for discovering 31% of NMEs; now jump to 2018, when 64% of all NME approvals originated from small pharma, a 103% increase over 2009.
In 2018 64% of the 59 FDA-approved drugs originated from emerging Biopharma Companies.
Big pharma’s new role in this is to partner and fund the innovation that it so sorely needs to bulk up its dwindling pipelines. This is a cost-effective move for larger drug companies to leverage outside scientific talent to gain access to breakthrough discoveries.
“This is a dominant trend in the industry,” says Nach Davé, VP, development strategy, Premier Research. “Large pharma is deciding that rather than take the risk of developing a single drug over the course of seven to 10 years and spending $7 billion, these companies are taking their chances on innovative, small companies.”
“The future R&D model will leverage the synergy that develops between those small companies, the grassroots innovators, and the remaining big pharma companies,” Mr. Munos, who is also a fellow at FasterCures, a Center of the Milken Institute, says. “There will still be challenges that will require scale to be overcome. Small entrepreneurial companies can do quite a lot, but they won’t be able to completely replace the capabilities of their big pharma counterparts.”
Mr. Davé predicts that small, innovative companies will continue to “do what they do best” in terms of science and be funded by large capital coming from the large pharma. Not only do big pharma companies have deep pockets but they also have the salesforces and the marketing muscle to get new drugs out to the masses. “It’s a very nice dynamic for the future and I see this model continuing to grow and get stronger and stronger,” he says.
Large pharma companies will never lose the marketing and sales muscle they have to drive the product to the marketplace, and that works well for the small biotech companies. “The relationship that we have now is very symbiotic and it’s advantageous when everyone continues to work in their own individual ecosystems,” Mr. Davé says.
He provides a real-life example of how this new symbiotic relationship and the ecosystem works. In the rare disease space, a small biotech company was developing a biologic that would treat only 700 people worldwide. The science was solid but getting funding was a struggle. “There weren’t a lot of people lining up to support a product that was going to have only 700 customers in the world,” Mr. Davé says. “And the price tag for development is the same whether developing a rare disease drug or a traditional hypertensive drug.”
Enter a large pharma partner operating in the oncology space. The pharma company was interested because the rare disease being addressed was a precursor to cancer, and the large pharma company saw funding the innovation as an opportunity. With that funding relationship came access to the biotech’s voucher that can be used to accelerate the timeline of any drug in the pipeline, which would prove very valuable to the large pharma partner.
Mr. Davé says the infusion of money from the large pharma company allowed the small biotech to produce a solution for 700 patients in the world and keep the price tag of the drug to a respectable level where it is still affordable and able to be reimbursed.
Over time, the budding relationships between large and small pharma may evolve to the point of a new business and R&D model across the entire industry. “We have started to witness a shift in the balance of power over the past decade, with a burst of innovation from the early-stage and emerging biotech companies,” says Naheed Kurji, CEO, Cyclica. “As the market landscape for drug discovery evolves, early-stage biotechs are increasingly entering the spotlight with a combination of subject-matter expertise in the science and the benefits of a lean organization conducive to rapid innovation.”
“The industry has become more open-minded about its business model, and more companies are getting bolder and starting to implement new ways of doing business,” Mr. Munos says. “The pharmaceutical industry used to be built on proprietary knowledge, tools, science, and data. This has changed.”
Innovation is now being energized by countless “mad scientists,” as Mr. Munos calls them, who work out of academia, incubators, or virtual companies.
“They add up to a giant grassroots innovation movement that operates on a shoestring,” he says. “Together, they explore emerging biology, and are quick to embark on translation when they spot an opportunity. It used to be that a biotech startup would need $50 million to get going because it had to recreate all the functions of a big company — HR, legal, and everything else. Today, companies don’t need this type of infrastructure. They can turn to crowdsourcing platforms, like scientist.com, for example. So, if you’re a chemist you focus on chemistry and procure everything else from the crowdsourcing platform when you need it. This flexibility has changed the dynamics of innovation. Startups now have the opportunity to grow without adding scale. This is a pretty valuable feature.
Crowdsourcing a Startup
“The crowdsourcing model is remarkable because it used to be that if someone wanted to start up a company, he or she needed to excel in everything, because the expertise was needed inside the company; procuring resources wasn’t very easy and the market was not transparent or efficient,” Mr. Munos says. “Today, if a company wants somebody to design a trial, clone a peptide, do a toxicology study, or synthesize one gram of a molecule, it can be easily resourced. All someone has to do is send an email to a crowd-sourcing platform and say, ‘Hey, I need that. Can you help?’”
There are several factors that have inspired and validated this model, effectively changing the pipeline in which medicines are brought to market. First, the patent cliff, as well as a significant decrease in new R&D returns, and the lack of discovery of more blockbuster drugs, to name a few. All of these factors led to big pharma looking toward smaller biopharma companies to develop innovations that it could not.
“Early-stage biotech companies are seizing the opportunity to grab their share of the market, with recent data from IQVIA suggesting that emerging biotech companies now account for more than 70% of the total R&D pipeline, up from 52% in 2003,” Mr. Kurji says. “Emerging and innovative biotechs will continue to decentralize the drug discovery pipeline and develop breakthrough treatments that offer greater benefits beyond incremental improvements and reshape the way medicines are discovered and brought to market.”
Funding Gets Easier
This emerging paradigm makes it easier for small or emerging companies to get funding, whereas before it was one of their biggest hurdles.
When small biotechnology companies had to rely on venture capital only, funding was difficult. If the VC-driven environment lost confidence in the biotechnology space or if fund managers lost confidence in certain medical innovations then the money stopped flowing in.
“Now, there is another player that has come to the table and that is large pharma, which has very deep pockets,” Mr. Davé says. “So, when a VC will not fund an innovative company or innovative product, these companies have at least another suitor that can fill that gap — big pharma.”
According to Mr. Kurji, large pharmaceutical companies are definitely supporting the creation, early-seed financing, and later-stage investment in biotech companies through their venture arms, but he also sees the venture capital ecosystem warming up to small pharma.
“There has been considerable interest in the small pharma and biotech industry, which has certainly captured the attention of VCs,” he says. “StartUp Health in its Q3 insights reports that there has been a considerable increase in both the funding amount and deal counts in the healthcare and pharma space. In 2010, there was $1.1 billion with 152 deal counts, which is in stark comparison to the $10.4 billion and 556 deals by Q3 of 2019, with the largest amount of funding focused on earlier stage healthcare companies.”
Not only has there been an increase in the number of deals and funding, there has also been an increase in the pool of investors supporting smaller biotechs and healthcare companies, with 1,061 unique investors participating in the industry, compared with 299 in 2012.
A large proportion of these investors are based in the United States, and most venture investments are focused around companies in Silicon Valley and Boston. There also has been recent growth in the Asian markets, particularly in China.
“As the market evolves, we will see a greater decentralization of resources as big pharma, non-profit organizations, and venture capital firms seek further innovation opportunities,” Mr. Kurji says.
Pharma Spinoffs Spur Innovation
In addition to funding innovation from outside sources, sometimes large pharmaceutical companies create their own spinoffs to discover and develop innovative products as an independent arm of the larger business. This model may operate differently from an independent startup, but there are many advantages over the cumbersome R&D model of big pharma.
“There are a number of pharma spinoffs that have emerged over the past decade,” Mr. Kurji says. “These spinoff companies typically take programs that have been discontinued or slowed down within the larger pharma company’s operations, and progress those programs independently with the appropriate rights and licenses. Cerevel is a great example, which spun out of Pfizer and is funded by Bain Capital. Cerevel is pursuing neurodegenerative disease, a therapeutic area that Pfizer recently divested its internal efforts.”
According to a company release, Pfizer is contributing a portfolio of precommercial neuroscience assets to Cerevel, which includes three clinical-stage compounds and several preclinical compounds designed to target a broad range of CNS disorders, including Parkinson’s, Alzheimer’s, epilepsy, schizophrenia, and addiction.
Funds affiliated with Bain Capital Private Equity and Bain Capital Life Sciences have committed $350 million with the ability to provide additional capital should it be needed in the future.
Bain Capital and Pfizer will support Cerevel in building a dedicated team of CNS scientists and life-sciences executives with extensive experience in clinical development of potential therapies for patients who have neurological and neuropsychological diseases.
“Unquestionably, pharma spinoffs operate differently from independent startups in two critical ways,” Mr. Kurji adds. “One, from the ideation of a pharma spinoff, there is a clear objective and strategy, and a visibility back to the pharma company, and two, the venture arms of a big pharma company are key as they financially support the ideation and creation of new companies that are strategically aligned to the pharma company’s mandates.”
While the hurdles that independent startups face are much higher than those of pharma spinoffs, there are advantages to being independent, he says. “An independent startup has more freedom to operate and try new things and pivot along the journey,” Mr. Kurji says.
Mr. Davé says the incubator concept within large pharma started gaining ground about three years ago.
“Large pharma companies started to create their own incubators and attract talent to those incubators,” he says. “I’ve seen many cases where top scientists from the academic space have shifted over to large pharma incubators where they’re still doing the same thing but the opportunities to advance their science and technology are better, because of the infrastructure that a large pharma company can provide.”
Many large pharma companies have started to move in this direction, realizing that it was a way to thrive and prepare for the transformation that is taking place in the industry.
“I’d say half of the top 12 pharma companies have a pretty good understanding of what’s going on,” Mr. Munos says. “They started long ago to prepare themselves for the transformation that is taking place. For instance, I remember when I first met Dr. Stoffels 10 years ago he would tell anyone who cared to listen that the model was broken and needed changing.”
Not surprisingly, years later, Dr. Stoffels was instrumental in developing JLABS at J&J, which now comprises 12 pharma incubators which are mentored but not funded by J&J, according to Mr. Munos. “This allows JLABS to explore emerging biology in 400 directions, something that could never be done within the company because it would raise its risk profile to unacceptable levels,” he says.
“But the purpose is to unleash innovation and it is working great guns.”
Mr. Munos also notes that Novartis, AstraZeneca, Bayer, Takeda, Boehringer Ingelheim, and Merck KGaA have retooled themselves in ways that have re-energized innovation.
The round up in his own words: “Novartis has gone through various iterations or versions of its innovation model. This was one of the first companies to return to scientists the freedom to innovate and the company has become one of the most prolific innovators, with 20 drugs approved in the last 10 years. AstraZeneca had a difficult transition, but its new drug output is rejoining the company to the leading innovators. Interestingly the mid-size companies such as Bayer, Takeda, Boehringer Ingelheim, Merck KGaA, seemed to have felt the heat a little sooner than their larger peers. But they all came to the realization that they needed to act in order to thrive in the new environment and they came up with new innovation models that have been remarkable. Takeda is a prime example of what we’re discussing because it used to be a rather staid company. Likewise, Boehringer Ingelheim came up with its own approach after realizing that much of the high-value innovation comes from outside. So it created a “research-beyond-borders” model that aims at harnessing new innovation ripples before they become waves. And its leadership has been pretty savvy at doing this. And Merck KGaA has taken multiple initiatives to basically implement open source R&D within its corporate structure.
“All this is taking place as we speak and it is changing the dynamics of research by boosting new drug approvals while harnessing the shoestring economics of startups,” Mr. Munos continues. “Basically, this is opening pathways to overcome the pricing and affordability challenges that companies have been facing. It is putting the industry back on a sustainable course.”
“When large pharma companies started to turn their attention to smaller biotech and emerging companies, innovation finally had a stage and an opportunity to be accelerated,” Mr. Davé says. “While we’re not producing $1 billion drugs, we are producing many more drugs that are providing solutions to a wider range of patients who were ignored or unattended to from a therapeutic perspective. Large pharma’s shift in focus away from billion-dollar drugs to more innovative drugs has proved beneficial to patients.”
With more companies and people engaging in innovation, there will be more ideas, more hypotheses, and more drug candidates that make it to the clinic. Scientific breakthroughs are quickly followed by the creation of multiple well-funded startup companies to exploit the new opportunities.
“This wasn’t the case 10 years ago, but now it’s become routine,” Mr. Munos says. “The reality is that if innovation is getting cheaper, we’re going to see more of it, and that’s exactly what is happening.”
Mr. Munos adds this as a “very exciting time” in the industry and there are many reasons to be optimistic about the future of the pharmaceutical industry. He anticipates that entrepreneur scientists and small companies will have a much easier route to achieving their goals than they have in the past.
“There will be a lot of turbulence in the near term, but in another five to 10 years or so, the industry will be on much better footing,” Mr. Munos says.(PV)
Innovation on Your Table
In 2018, a team of researchers at MIT, led by J. Christopher Love, Ph.D., engineered a miniaturized biopharmaceutical factory that could fit on a dining room table and produce hundreds to thousands of doses of a needed treatment in about three days.
As published in the journal Nature Biotechnology, this on-demand manufacturing system is called Integrated Scalable Cyto-Technology (InSCyT). It is fully automated and can be readily reconfigured to produce virtually any approved or experimental vaccine, hormone, replacement enzyme, antibody, or other biopharmaceutical. With further improvements and testing, InSCyT promises to give researchers and healthcare providers easy access to specialty biologics needed to treat rare diseases, as well as treatments for combating infectious disease outbreaks in remote towns or villages around the globe.
The researchers report that it took them about 12 weeks to devise the processes needed to produce each drug. That’s compared with a year or two that is normally required to get a more traditional, large-scale manufacturing operation up and running.
Source: NIH Director Dr. Francis Collins, NIH Blog
Emerging Company Trends
Emerging biopharma companies account for 72% of all late-stage pipeline activity, up from 61% a decade ago. During the next five years, trial productivity will be heavily influenced by 8 key trends, according to an IQVIA Clinical Development Trends Impact Assessment.
1. Digital health technologies will enable the capture of drug efficacy and safety data remotely, which can improve patient safety, enable virtual trial formats, and ease site work burden.
2. Patient-reported outcomes will shed new light on patient experience and drug efficacy and safety outside the clinical setting and lead to accelerated trial times as endpoints shift.
3. Real-world data will optimize trial design, speed investigator and site selection, and enable new trial designs by acting as virtual control arms and supporting pragmatic, adaptive, and RWE registry trials.
4. Predictive analytics and artificial intelligence will identify new clinical hypotheses, reduce trial design risks and speed enrollment by identifying protocol-ready patients.
5. Shifts in types of drugs tested, for instance, to targeted therapies and next-generation biotherapeutics that improve efficacy and success rates and have accelerated development timelines but require longer-term patient follow-up.
6. Biomarker testing availability to help narrow patient populations to those more likely to see effect, resulting in improvements in efficacy, safety and success.
7. Regulatory landscape changes will encourage the adoption of precision medicine approaches, novel trial designs, and endpoints while providing means for accelerated drug approvals and regulatory success.
8. Pools of pre-screened patients and direct-to-patient recruitment will facilitate enhanced trial enrollment, shortened trial duration, and faster market availability.
Source: IQVIA Institute for Human Data Science Study
https://www.pharmavoice.com/article/2020-01-pharma-innovation/
Once ENZC advances the HIV and Covid 19 therapies and the Big Pharma sees how disruptive and powerful the technology is then numbers are crunched and no one Big Pharma will be able to afford to buy ENZC's portfolio so they have to each buy what piece they can afford.That is if ENZC is willing to sell.
What is ENZC?
A little ole Biotech Committed to the Development of Proprietary Antiviral Peptides and Monoclonal Antibody for Treating Debilitating Infectious Diseases
What is ENZC Mission?
Our mission is clear – to create therapeutics that are effective and affordable for treating infectious diseases that plague the world. This goal includes the development of therapeutics and monoclonal antibodies targeting infectious diseases, including the CoronaVirus.
Our ultimate objective is to provide such therapeutics to improve health around the world.
What is their plan of action?
Enzolytics, Inc. is a drug development company committed to the commercialization of its proprietary proteins for the treatment of debilitating infectious diseases. Enzolytics is committed to developing monoclonal antibody therapy and treating infectious diseases.
What assets does ENZC possess?
Intellectual property:
2 Patents with 14+ patents pending.
Proprietary Cell Line Producing Clone 3 anti-HIV monoclonal antibody
Proprietary Methodology for Producing Fully Human Monoclonal Antibodies
Human Capital:
Charles S. Cotropia – CEO and Chairman of the Board
Joseph P. Cotropia, MD – Chief Medical Officer and Director
Harry H. Zhabilov – CSO and Director
Gaurav Chandra, MD – Chief Operating Officer and Director
Ronald Moss, MD – Scientific Advisor
RABID Shareholders:)
Who are our Partnering Labs For Implementing Our Technologies?
Genscript Labs
The production of recombinant Monoclonal Antibodies from parent antibodies, necessary for patient treatment.
University of Strasbourg, France
Dr. Christiane Moog, MD, Research Director at INSERM U1109, HDR PBMC, In vitro neutralization testing of anti-HIV Monoclonal Antibodies.
California National Primate Research Center
Koen Van Rompay, D.V.M., Ph.D., Univ. of California Davis, California, Koen Van Rompay. Macaque trials of anti-HIV Monoclonal Antibodies.
Creative Biolabs
Custom recombinant Monoclonal Antibody production and large-scale antibody manufacturing.
Lonza
Enzolytics and Lonza Bioscience are combining their respective technologies to fast-track development and production of anti-HIV and anti-SARS-CoV-2 Monoclonal Antibodies produced by Enzolytics.
These Partnering labs are there to assist in moving our technology forward.
Just think about what Charles said about the licensees already lining up to get a piece of the ever growing pie.
Every time ENZC reaches a significant milestone they become more and more valuable.
We are encouraged by the positive feedback received from pharmaceutical companies who have acknowledged an interest in partnering upon achievement of defined milestones.
That statement above will come to be after certain milestones are met and then BIG Pharma comes into play. It is my belief that ENZC may license/sell certain technologies (first with HIV and Covid 19 therapies) however if ENZC wants to ensure all their possible technologies make it to the marketplace they have to continue to develop the technologies for other diseases.
If ENZC was to sell the company outright then whoever buys it can do what they want with the technology.
Dr. Chandra said is best during last weeks video:
This is very exciting
This is a very important milestone for ENZC when a company like Lonza decides to collaborates with us.
This is a very important milestone for ENZC when a company like Lonza decides to collaborates with us.
We have had discussions with large pharmacueticals companies.
There are tremendous interest in both the antibodies.
We have been offered interest in collaboration, partnership/acquisition of assets with a milestone based requirement.
We anticipate there will be a partnership with a larger entity before the twelve period when the IND will be applied on both of the antibodies.
Final Thoughts:
We all are here to make money however as most know there are no guarantees.
This is a HIGH Risk HIGH REWARD investment. The risk goes down everyday as we move closer to certain milestones.
There are some predictive patterns to how biotech stocks start impressive runs and sometime Big Money loses patience and decides to make a move.
The current company only got started 9 months ago and look at all what it has accomplished. There has been bumps in the road and ENZC made adjustments to continue on to their objectives. One of the biggest setbacks was having to do the clinical trials again in Europe. Charles rolled up his sleeves and figured out what to do.
There will more bumps and more adjustments and I'm confident Charles will figure it out.
The Pot of GOLD is just months away however there will be nuggets leading us there along the way.
Some select Lonza historic achievements:
1897
Foundation of Lonza AG Electricity Works in Gampel, Valais (Switzerland), on the banks of river Lonza. The electricity was used to manufacture calcium carbide and acetylene.
2010
Lonza signs agreement with GlaxoSmithKline (GSK) to secure capacity and expertise in biological manufacturing to support ongoing development of GSK’s biopharmaceuticals portfolio. Thereby, Lonza will supply manufacturing capacity for five early-stage monoclonal antibodies.
https://www.gsk.com/en-gb/media/press-releases/gsk-signs-agreement-with-lonza-to-secure-capacity-and-expertise-in-biological-manufacturing-to-support-ongoing-development-of-gsk-s-biopharmaceuticals-portfolio/
2011
Lonza expands its viral-based therapeutics business with the construction of a new, state-of-the-art cGMP clean room located adjacent to its existing Houston, TX (USA) operations.
2014
Bristol-Myers Squibb and Lonza expand manufacturing agreement. The contract expansion will include the production of commercial quantities of a second Bristol-Myers Squibb biologic medicine at Lonza’s mammalian manufacturing facility in Portsmouth, NH (USA).
Lonza signs exclusive agreement with Index Ventures for the development and manufacture of biologics for portfolio companies.
Lonza extends partnership with Pharmacyclics to support manufacturing of recently approved oncology therapeutic, IMBRUVICA™.
2015
Lonza signs a long-term manufacturing supply agreement with Alexion, under which Lonza will construct and launch a new suite dedicated to Alexion in Portsmouth, NH (USA).
2018
Lonza opens world’s largest dedicated cell- and gene- therapy manufacturing facility in Houston, TX (USA).
2020
Lonza entered into a landmark ten-year collaboration agreement with Moderna Inc. to manufacture the drug substance for Moderna’s COVID-19 Vaccine, alongside other mRNA-based collaboration projects from Moderna’s innovation pipeline.
Lonza announced an agreement to manufacture AstraZeneca's COVID-19 long-acting antibody combination.
https://www.fiercepharma.com/manufacturing/astrazeneca-taps-lonza-to-churn-out-drug-substance-for-covid-19-antibody
2021
Lonza was recognized by Ethisphere® as one of the world's most ethical companies in 2021.
Enzolytics and Lonza Bioscience Combine Technologies to Fast-track Development and Production of Anti-HIV and Anti-SARS-CoV-2 Monoclonal Antibodies produced by Enzolytics
https://www.lonza.com/company-overview/our-history
Many many questions about Lonza and ENZC relationship.
Most probably won''t be answered due to confidentiality however some must be due to disclosure requirements.
Here are my thoughts on our relationship with Lonza:
Lonza undeniably understands what ENZC is trying to accomplish.
They understand the science, the technology and the methodology.
Lonza have the tools and facilities to gets us where we want to go(FDA IND) with proven success.
Lonza signs many types of agreements and if things do well they are inclined to extend them.
Lonza will be a nice fit for ENZC. Just what the doctor ordered.
Bain, Cinven buy Lonza Specialty Ingredients in $4.7 billion deal
ZURICH (Reuters) - Bain Capital and Cinven are acquiring Lonza’s Specialty Ingredients division in a deal worth $4.7 billion, the Swiss contract drug maker said on Monday, as it focuses on its faster-growing unit that supplies drug and biotech companies.
The Bain-Cinven consortium had been listed with Germany’s Lanxess and buyout groups Advent, Carlyle and others as bidders for the unit that makes anti-dandruff shampoo ingredients, nutritional supplements for swine and microbial controls for wood and hygiene products.
Lonza, which said the enterprise value of the transaction is 4.2 billion Swiss francs ($4.7 billion), is doubling down on its accelerating drug business. Its customers include Moderna, which Lonza supplies with ingredients for its COVID-19 vaccine, and AstraZeneca, which hired the Swiss company to help make its COVID-19 antibody treatment.
“The sale of the Specialty Ingredients business will allow Lonza to focus on its position as a leading partner to the healthcare industry,” said Chairman Albert Baehny in a statement.
“The free cash flows resulting from the sale will allow us to accelerate our strategic priorities,” he added.
Lonza’s shares rose more than 60% last year, as it expanded in drugs and prepared to unload Specialty Ingredients.
The unit, once Lonza’s mainstay before the ascendant drugs and biotech division relegated it to the back burner, saw revenue fall 2.1% last year to 1.7 billion francs last year.
By contrast, Lonza’s drug, biotech and nutrition revenue rose 7.2% to 4.5 billion francs as Lonza pushed ahead with a big expansion, including building four new production lines for Moderna’s vaccine against the new coronavirus in the United States and in Switzerland.
Top companies in Cell Culture
Cell culture is used in identifying the cause of disease as cells are easily manipulated using external growth factors and changing physiological conditions. In addition, the cells can act as in vivo system and hence the internal signaling pathways can be studied accordingly. Cell culture is now used for studying the effect of the drug and simultaneously useful in medicinal purpose. Also, currently, scientists are using stem cells for studying the metabolic pathways, medicinal purpose, and organ regeneration.
Here are the leading 10 companies in Cell Culture Market-
Merck & Company Incorporation
Irvine Scientific
GE Healthcare
Agilent Technologies
Thermo Fisher Scientific
Lonza
Founded in 1897 and headquartered at Basel, Switzerland; Lonza is engaged in custom development and manufacturing of active pharmaceutical ingredients to innovative dosage forms for the pharma and consumer health and nutrition industries. The company operates through two business segments: pharma& biotech, and specialty ingredients. The company offers products under 1,000 brands across the world. The company provides cell culture products in the pharma & biotech business segment.
With its subsidiaries and a strong network of distribution, the company has a leading position in North America, Europe, Asia Pacific, and other countries.
Corning Inc.
Sera Care Life Sciences Incorporation
Becton Dickinson
CellGenix GmbH
https://meticulousblog.org/top-10-companies-in-cell-culture-market/
Priceless
Charles is a visionary and Lonza sees the light and maybe setting itself up to be part of ENZC processes for years to come.
It will take many companies to work on the products ENZC will be producing.
Just think about what Charles said about the licensees already lining up to get a piece of the ever growing pie.
Every time ENZC reaches a significant milestone they become more and more valuble.
The PICTURE of ENZC was BLURRY when they gave us Milestones timelines on 4/19/2021:
We are encouraged by the positive feedback received from pharmaceutical companies who have acknowledged an interest in partnering upon achievement of defined milestones. The milestones we have set include the following:
Monoclonal Antibodies for Treatment of HIV Milestones
1st Milestone: Testing of anti-HIV Monoclonal Antibodies at University of Montana
Status: in process. Time to completion: 1 month
2nd Milestone: Broad-based neutralization testing of existing anti-HIV Monoclonal Antibodies at University of Strasbourg, France
Status; in process. Time to completion: 2 months
3rd Milestone: Animal Studies of anti-HIV Monoclonal Antibodies at California National Primate Research Center, University of Southern California
Time to completion: 6 months following in vitro testing in process.
4th Milestone: Using Artificial Intelligence, identification of additional conserved immutable target sites (epitopes) on the HIV-1 virus
Status: Completed
5th Milestone: Production of additional Monoclonal Antibodies targeting identified sites (epitopes) on the HIV virus
Status: in process. Time to completion: 5-6 months
COVID-19
We are proud of the significant advances we have made in the development of Monoclonal Antibodies for treating Covid-19. We have reported that the Monoclonal Antibodies being produced by the Company will target immutable, conserved sites on SARS-CoV-2 (Coronavirus) that exist on the variant strains of the virus from the UK, Brazil, and South African.
These findings are considered highly significant in that the Center for Disease Control ("CDC") has reported these "variants of concern" are ones "for which there is evidence of an increase in transmissibility, more severe disease (meaning increased hospitalizations or deaths), a significant reduction in neutralization by antibodies generated during previous infection or vaccination, reduced effectiveness of treatments or vaccines, or diagnostic detection failures."
Our AI platform developed in collaboration with Denver Scientific has been one of our many successes. The patentable discoveries will be significant in our ongoing partnering dialogue with pharmaceutical companies interested in treatments for the Coronavirus and numerous other infectious diseases.
We intent to expedite our development of anti-Coronavirus Monoclonal Antibodies including an eventual fast-track clinical trial to progress to market.
SARS-CoV-2 (Coronavirus) Monoclonal Antibodies Milestones
1st Milestone: Using Artificial Intelligence, identification of conserved immutable target sites (epitopes) on the Coronavirus
Status: Completed
2nd Milestone: Production of Monoclonal Antibodies targeting identified sites (epitopes) on the SARS-CoV-2 virus
Status: In process. Time to completion: 3-4 months
3rd Milestone: Fast-Track Clinical Studies
Time to Completion: 6 months following production of Monoclonal Antibodies
ITV-1 anti-HIV Therapeutics
Clinical trials are planned for the Company's patented anti-HIV therapeutics ITV-1. Earlier this year, we announced the execution of Articles of Association to form International Medical Partners ("IMPL"), a Bulgarian Limited Liability Company of which the Company is 50% owner. The Company's partners in IMBL will fund the total cost of the Clinical trials under the European Medicine Agency (the "EMA") standards and the application cost for the EMA permit for the Company's ITV-1 patented therapeutics for treating HIV. Under the Mutual Recognition Agreement (the "MRA") between the EMA and the United States Federal Drug Administration (the "FDA"), the Company believes that issuance of the EMA permit for the ITV-1 compound could qualify ENZC's treatment for recognition by the FDA. IMBL has entered negotiations to engage a CRO to begin the clinical trials required under EMA standards.
We will have a definitive timeline for the expected date of initiation and completion of clinical trials in the coming weeks.
Production of Monoclonal Antibodies for HTLV-1/2
We are committed to developing "universal, durable and broadly neutralizing" Monoclonal Antibodies for many infectious diseases. We have an "intent to partner" agreement with a pharmaceutical company to create Monoclonal Antibodies against HTLV-1/2. We expect to complete the production by the end of 2021.
Monoclonal Antibodies for HTLV-1/2
1st Milestone: Using Artificial Intelligence, identification of conserved immutable target sites (epitopes) on the HTLV1/2 virus
Time to Completion: 2-3 months
2nd Milestone: Creation of anti-HTLV1/2 Monoclonal Antibodies
Time to completion: 6-8 months following identification of target epitopes
CEO Charles Cotropia said, "The strength of our company lies in our multiple technology platforms and the ability to produce fully human Monoclonal Antibodies against conserved and immutable targets on identified viruses. The viruses that may be addressed using our technology range from HIV to the Coronavirus to HTLV-1/2 to Ebola and many more. These numerous targeted viruses and bacteria are listed on our website [http://enzolytics.com/proprietary-therapeutics/]. We will continue to provide updates on our developments and progress toward completing the milestones we have set. We thank all our shareholders for their ongoing support of our Company and its technologies."
The PICTURE of ENZC was very, very CLEAR when they gave us an update timelines on 7/22/2021:
It is All about the MILESTONES!!!
I'm not interested in contacting my congressman about ENZC or any stock being manipulated.
When ENZC produce the right results the stock will move. I have complete confidence that they will produce these results it will be reflected in the stock price.
Why?
Charles is in Charge!!!
Today's interview was awe inspiring.
ENZC is moving along producing results, reaching milestones and collaborating/partnering/licensees with other companies.
ENZC collaboration with Lonza is HUGE,
Lonza is not only a pink company it is a "Blue Chip" multi-billion dollar, muliti-national corporation that have the tools ENZC need to advance their future product. Anyone interested in ENZC and don't take a close look at Lonza is missing a huge and important piece of ENZC game plan.
Dr. Chandra said is best:
This is very exciting
This is a very important milestone for ENZC when a company like Lonza decides to collaborates with us.
Lonza is a very very BIG company...
We have had discussions with large pharmacueticals companies.
There are tremendous interest in both the antibodies.
We have been offered interest in collaboration/partnership/acquisition of assets with a milestone based requirement.
We anticipate there will be a partnership with a larger entity before the twelve period when the IND will be applied on both of the antibodies.
The bottom line for ENZC is simple. It is a small biotech trying to get it product to the market. As ENZC moves along in their processes and reaches certain milestones their value increases. They are working on some very precious technology that there is tremendous interest in and will only grow larger.
Anyone who hasn't seen the interview it is worth a look.
Today we talk @enzolytics - DO NOT miss this session folks! See you soon @drgauravchandra | https://t.co/x2Ikgd1ayt #AI #covid $ENZC
— James Hicks (@jameshicks) July 22, 2021
Have you contacted your US Congress Person.
They are very receptive to the people they serve.
You are a shareholder.
It does not matter where the company is located.
Why does QNTA keep going up?
How many green days have we had recently?
Is the latest FDA requirement getting closer to be completed?
Is QNTA the best Biotech play on the OTC?
Intel AI is good exposure and tools for ENZC and great advertisement for Intel.
While it would be wonderful for Intel to fund ENZC the likelihood of that happening is slim to none.
Intel is a technology company with a capital arm called Intel Capital investments that primarily and more likely exclusively invests in other technology companies as that is their area of expertise.
If they were to start investing in companies outside their area of expertise and it doesn't go well they would have a major problem with their shareholders.
Good question Abner Doubledip.
I was thinking the same thing.
Maybe an 8K drops by weeks end explaining these details.
Overall though Lonza is not only a high value pink it is a "Blue Chip" multi-billion dollar, muliti-national corporation that have the tools ENZC need to advance their future product. Anyone interested in ENZC and don't take a close look at Lonza is missing a huge and important piece of ENZC game plan.
This is a huge step and puts up right in "Big Pharma" neighborhood.
Lonza is a GREAT company to Combine Technologies to Fast-track Development and Production of Anti-HIV and Anti-SARS-CoV-2 Monoclonal Antibodies produced by Enzolytics
Stock information
LONZA GROUP AG-REG
(LONN.SW: SIX Swiss Ex)
Last price:
CHF 662.60
Our Businesses
Pharma Biotech & Nutrition
4.5bn Sales in CHF
Lonza at a Glance
13,856 Employees (Full-Time Equivalent)
31.2 CORE EBITDA margin in %
1,406m CORE EBITDA in CHF
24.3 CORE EBIT margin in %
4,508m Sales in CHF
12.0% Sales Growth in %
9.6 ROIC in %
569 Active patent families
>1,065 Small and large molecules
5,278 Trademark filings
792 Brands
Our Strategic Focus
Throughout our 123-year history, the Lonza business strategy has been to respond dynamically to the demands and opportunities of the external environment. This has been a key factor in our growth and success. 2020 provided a unique operating environment, as the business world absorbed and learned to manage the impacts of the COVID-19 pandemic. True to our heritage, we remained agile to these developments by maintaining a strategic focus on internal evolution and external adaptation.
Internally, the decision to divest the Lonza Specialty Ingredients (LSI) segment provided an opportunity for us to refocus on our objective to consolidate our position as a leading partner to the healthcare industry. Concurrently, we remained responsive to the demands of the pandemic, and the developments of the industry. This strategic approach has enabled us to deliver a strong set of financial results while ensuring that the business is set up for long-term success. Importantly, it has also allowed us to make an active and decisive contribution to controlling the pandemic.
Structural Design
The decision to divest the LSI segment has allowed us to focus our energy and attention as a pure-play partner to the healthcare industry. In this context, we have redesigned the Lonza company structure to meet customer needs and expectations, as well as delivering optimal levels of productivity and efficiency. From 1 January 2021, our businesses have been placed into four divisions, each of which are set out below. From 2021, we will report the financial performance for each division.
Small Molecules
Active Pharmaceutical Ingredients
Drug Product Formulation
Biologics
Mammalian
Microbial
Licensing
Bioconjugates
Parenteral Drug Product Services
mRNA
Cell & Gene
Cell & Gene Technologies
Personalized Medicine
Bioscience
Capsules & Health Ingredients
Capsules
Health Ingredients
Business Performance
In the context of the COVID-19 pandemic, we have redoubled our focus on ensuring business continuity and maintaining resilience. We have worked to strengthen our supply chain and increase our free cash flows, while implementing new safety measures to ensure that employees can still safely attend our manufacturing plants and laboratories. We have been impressed by our people’s resolve, dedication and energy throughout the pandemic, as they have adapted to their new working conditions.
To further improve margins during a time of high CAPEX investment, we have redoubled our efforts to deliver lean operations, while maintaining our focus on quality. Although speed has always been an important consideration for our customers, it has become a critical necessity in the context of the COVID-19 pandemic. Our agreement to manufacture the drug substance for Moderna’s COVID-19 Vaccine progressed from contract negotiations to production in eight months at our site in Visp (CH), and even more rapidly in Portsmouth (USA). The pre-built capacity provided by our Ibex® Solutions offering has been instrumental in accelerating delivery timelines, and has provided advantages to our customer’s business, as well as wider societal benefits.
Innovation
We understand that innovation provides a point of differentiation for our business. We drive innovation with new manufacturing processes, as demonstrated by our work to deliver the mRNA platform in the Moderna COVID-19 Vaccine drug substance. We are also working on process innovation by increasing automation to streamline human intervention. This can be seen in our Cocoon® Platform, which improves efficiency in cell therapy manufacturing by providing an automated, closed production platform.
Our approach to innovation further extends across the entire breadth of our divisional offerings from small molecules to biologics. Our Ibex® Solutions offering provides pre-built capacity that can deliver drug product for clinical trials, and expedite clinical and commercial production. We are also extending our capabilities in meeting our customers’ complex manufacturing needs, across a wide variety of products and services.
Sustainability
Sustainability is a strategic priority for our business. We have an ethical responsibility to protect the environment, promote diversity and invest in our local communities. It is also an increasing priority for our customers, investors and employees.
We have an established track record in delivering improved levels of environmental stewardship. We are reducing our energy consumption and carbon footprint, while refocusing on renewable energy resources. We are also continuing to decrease our industrial water intensity.
Alongside these important measures, we are taking steps to become a more inclusive and purpose-led organization. In 2020, we established a global Diversity and Inclusion Taskforce to ensure that we provide a welcoming environment in which colleagues are valued for their differences of characteristic, preference, perspective and belief.
We have also worked on multiple community investment projects across the locations and markets in which we operate. Among other projects, in response to the COVID-19 pandemic, we provided disinfectant solutions and personal protective equipment to hospitals in Switzerland and the US, while supporting critical hygiene projects in India.
Long-term Focus
All four of our business divisions operate in growing markets, and our long-term demand forecasts have left us confident to make significant and sustained investments in capacity expansion. We plan to maintain existing levels of CAPEX expenditure for the next two years, to ensure that we fully capitalize on market growth opportunities. In the short term, we are working to improve margins by managing our OPEX, when facilities and operations come online and commence ramp-up. Looking to the longer term, these investments are set to deliver sustained growth while differentiating the scope and scale of our offerings.
Q&AS ABOUT CREATIVE BIOLABS
Creative Biolabs is specialized in providing custom biotechnology and pharmaceutical services that cover the full scope of biotechnology needs of early drug discovery and development. As a trusted provider of the most cost-effective outsourcing solutions, Creative Biolabs has been working for a large number of clients from biotechnology and pharmaceutical companies as well as government and academic research laboratories all over the world.
What is the company's mission?
Its mission is to help researchers and scientists achieve their goals in the field of antibody related studies, by providing them with reliable products, services and customized solutions. It strives to be more than just a service provider, but a research partner that customers can rely on in exploring more in antibody study.
Describe the company’s most popular service offering.
Creative Biolabs has 3 main branches of services, antibody discovery, engineering and bio-manufacturing. Among them, antibody engineering services are by far the most popular offerings, such as antibody sequencing, antibody gene editing and post translational modification.
Why should customers use its services? Does it save time and/or money and/or provide access to innovation?
Creative Biolabs was founded by a group of scientists dedicated to the conquering of life-threatening diseases, therefore, it knows for sure about what the researchers and scientists expect from service suppliers like us. Since the establishment in 2005, it has been working for a large number of clients from biotechnology and pharmaceutical companies as well as government and academic research laboratories from over 26 countries, saving them plenty of time and money. Its scientists group always works closely with the clients. They are available for any consults about the project 24 hours a day, so as to push forward the processes smoothly.
What new services, tools or technologies will it offer over the next 2 years?
Antibody humanization will be its major focus in the next two years. Of course, it will also continue to expand our services in antibody discovery, engineering and bio-manufacturing.
What is the company doing to remain an industry leader?
Its marketing department and research team always follow closely with the biotech market especially antibody focused areas, by inviting client reviews, doing marketing researches, attending international conferences and so on. In this way, it can always know what the market is currently looking for. Besides, it’ll have one expert team follow closely with every process of each project from our clients, so as to make everything perfect.
The stock is not going to make any significant movement until something dramatic happens with QNTA such as major increase in revenues, IND approval, partnership or some other major catalyst.
QNTA has a lot going on and many things will happen in the upcoming weeks and months.
The right catalyst can explode the stock price in a heartbeat.
This stock is not headed down a dead end.
It is on a road trip with down the FDA freeway with detours along the way. However QNTA will reach their intended destination which is IND application approval.
Detour
Subsequent to the acknowledgement of the trial, the FDA has requested that the Company complete two additional toxicology studies in animals. Since adoption of COVID-19 vaccinations, the FDA altered its protocol for measuring toxicology to include studying it at the DNA level. As this is a newer development, the agency has asked Medolife to provide data in this regard. Medolife has the product and protocol necessary to complete these studies in short-order.
Will there be more detours?
We will find out after QNTA submits the two addition toxicology studies.
We have people in our camp that should help to get us through the FDA approval process:
DiArcangelo has 24 years of experience in the global biotechnology, pharmaceutical, device, and nutraceutical industries and has worked on products that have received FDA approval on 25 pharmaceutical drugs.
The question what it he "BIG UPDATE"?
1. Partnership
2. Money
3. Financials
4. Buy Out/In
5. ???
$ENZC has big update coming early next week...#infectiousdiseases #COVID19 #HIV #H10N3 #AIDS #Cure #WhitePaper #Intel #technology #trading #stock #StockMarket #OTC #OTCStocks #ad #cnn
FDA is not OWNED by USA Big Pharma
While I believe there is probably plenty of the conflicts of interests and other shaky happenings, the FDA cannot mess with not approving drugs that meet their approval criteria and disapproving drugs that do not.
It would not only be ethically wrong, it could be criminally charged.
Just think about what the FDA was facing when QNTA showed up with their application:
SCORPION VENOM
There may have been laughter and who knows what else.
There was not much if any clinical trials or peer reviews.
Once QNTA started presenting the data from their at least since January and provided a wealth of data in March:
The Company assembled detailed information regarding the manufacturing of Escozine®, clarity on dosing, as well as both previous and new safety and efficacy data derived from an on-going human study taking place in the DR. The study has been conducted on over 500 participants and intends to demonstrate the safety and efficacy of Escozine®. Escozine® is a polarized solution of the Rhopalurus princeps scorpion peptide owned by Medolife, which has been filed with the FDA under the IND regulatory pathway as well as the Ministry of Health in the DR where the Company is seeking product registration. Previous clinical data was submitted to the FDA including preliminary results of the safety study, which has now been expanded upon. This data, as well as the batch of Escozine® that was produced specifically for the FDA, has now been submitted. After the review of the data and barring any further inquiries or requests, the FDA will designate IND status for Escozine®, essentially allowing the drug to be distributed in the US. After such designation, the Company will pursue other clinical applications of Escozine®, including as a potential cancer therapeutic where the Company has already released positive clinical results.
This current DNA Toxicology requirement QNTA is working on hopefully will clear the way for approval once it is completed.
While the FDA has open up the flood gates to get solutions for Covid 19 into the marketplace, they still have to do their due diligence before approving/disapproving drug candidates.
Escozine is an unusual to say the least drug candidate that probably has come through the FDA in its' entire history.
This may be one for the History Books.
Agreed 100%.
Are we there YET?
Approval looks to be close for the IND.
The added DNA toxicology study pushed back our approval day:
The company has been tasked with measuring toxicology at DNA level:
Subsequent to the acknowledgement of the trial, the FDA has requested that the Company complete two additional toxicology studies in animals. Since adoption of COVID-19 vaccinations, the FDA altered its protocol for measuring toxicology to include studying it at the DNA level. As this is a newer development, the agency has asked Medolife to provide data in this regard. Medolife has the product and protocol necessary to complete these studies in short-order.
This stuff is used by a lot by humans for other reasons than medical.
Using a serum or moisturizer that contains peptides can lead to firmer, younger-looking skin, and maybe even fewer breakouts. Peptides are generally considered safe, and while they're a promising skin care ingredient, more research is needed on their efficacy.
Not quite what FDA said.
QNTA already has done animal toxicology studies.
The FDA requested "TWO ADDITIONAL STUDIES".
FDA Accepts COVID-19 Clinical Study and Advises on Next Steps for Pre-IND Filing by Medolife Rx
As the Company expected, it received a detailed response from the FDA on its Pre-IND originally filed on April 27, 2020. The response included: recognition from the FDA on the therapeutic effects of Escozine®, validation of the Company’s clinical trial as an informal proof-of-concept study, and laid out very specific guidelines for the next steps required by the regulatory body in order to garner approval for Escozine® as a treatment for COVID-19.
Subsequent to the acknowledgement of the trial, the FDA has requested that the Company complete two additional toxicology studies in animals. Since adoption of COVID-19 vaccinations, the FDA altered its protocol for measuring toxicology to include studying it at the DNA level. As this is a newer development, the agency has asked Medolife to provide data in this regard. Medolife has the product and protocol necessary to complete these studies in short-order.
Until we get FDA approval the PPS will be up and down.
I don't know however we should be fast tracked.
July 08, 2021
Escozine®, which is comprised of scorpion peptides that have been polarized by the Company’s proprietary process, is Medolife’s lead drug candidate. The Company recently announced that it has received a detailed response from the US Food and Drug Administration (FDA) on its Pre-Investigational New Drug (Pre-IND) submission on Escozine® as both a potential palliative and therapeutic drug for the COVID-19 virus. In the response, the FDA acknowledged the Company’s clinical trial that took place in the DR as a proof-of-concept study and provided detailed guidelines for next steps in its approval process. The Company is in the process of outlining an additional DNA toxicology study as well as a formal clinical Pharmacokinetic (PK) study that it hopes to launch in short order.
June 23, 2021
(OTC PINK: QNTA), announced today that the Company has received a response from the U.S. Food and Drug Administration (FDA) relating to its Pre-Investigational New Drug (Pre-IND) filing on its lead drug candidate Escozine® for the treatment of the SARS-CoV-2 (COVID-19) virus. The response validated the Company’s clinical study conducted in the Dominican Republic (DR) and outlined next steps for its approval process in the US.
As the Company expected, it received a detailed response from the FDA on its Pre-IND originally filed on April 27, 2020. The response included: recognition from the FDA on the therapeutic effects of Escozine®, validation of the Company’s clinical trial as an informal proof-of-concept study, and laid out very specific guidelines for the next steps required by the regulatory body in order to garner approval for Escozine® as a treatment for COVID-19.
Subsequent to the acknowledgement of the trial, the FDA has requested that the Company complete two additional toxicology studies in animals. Since adoption of COVID-19 vaccinations, the FDA altered its protocol for measuring toxicology to include studying it at the DNA level. As this is a newer development, the agency has asked Medolife to provide data in this regard. Medolife has the product and protocol necessary to complete these studies in short-order .
April 13, 2021
The Company assembled detailed information regarding the manufacturing of Escozine®, clarity on dosing, as well as both previous and new safety and efficacy data derived from an on-going human study taking place in the DR. The study has been conducted on over 500 participants and intends to demonstrate the safety and efficacy of Escozine®. Escozine® is a polarized solution of the Rhopalurus princeps scorpion peptide owned by Medolife, which has been filed with the FDA under the IND regulatory pathway as well as the Ministry of Health in the DR where the Company is seeking product registration.
Previous clinical data was submitted to the FDA including preliminary results of the safety study, which has now been expanded upon. This data, as well as the batch of Escozine® that was produced specifically for the FDA, has now been submitted. After the review of the data and barring any further inquiries or requests, the FDA will designate IND status for Escozine®, essentially allowing the drug to be distributed in the US. After such designation, the Company will pursue other clinical applications of Escozine®, including as a potential cancer therapeutic where the Company has already released positive clinical results.
“The FDA-approved therapeutic drug market is the gold standard globally and should we receive IND designation from the FDA, it would catapult our other research across the world,” said Medolife CEO Dr. Arthur Mikaelian. “Submission to the FDA is never easy, but we are generating such positive clinical trial results that we are confident the regulatory body will take notice. They have been reviewing our submission for some time, requesting various other information that we have now submitted. I believe this could be the last request ahead of approval, which would be tremendous not only for our Company, but for patients who are in need of a solution where one does not currently exist. An approval from the FDA would also propel interest from the scientific community on the potential therapeutic benefits of the natural peptides we are studying, including investment and partnership interest.”
March 18, 2021
(OTC PINK: QNTA), announced today positive results in a safety and toxicity study conducted on its polarized drug candidate derived from a small molecular peptide found in scorpions, designed to treat patients with the SARS-CoV-2 virus, also known as COVID-19. The results showed no signs of toxicity in any of the patients involved in the study who were given the drug Escozine®, which is a polarized solution of the Rhopalurus princeps scorpion peptide owned by Medolife.
The study, which was conducted in Santo Domingo of the Dominican Republic under the supervision of medical principal investigators, was conducted on over 500 patients, where data from one group of patients was used in the Company’s FDA pre-IND filing. Each patient was given Escozine® sublingually four times a day. During and after administration, a complete blood count (CBC) was conducted on each patient where the researchers measured various parameters to evaluate if the drug candidate was safe, such as hemoglobin (Hb), hematocrit (HCT), and red blood cells (RBCs) levels. There were no significant differences observed before or after administration. Additionally, there were no significant differences observed in white blood cells (WBCs), neutrophils, lymphocytes, monocytes, or eosinophils, concluding that the drug candidate was safe and non-toxic.
March 09, 2021
(OTC PINK: QNTA), announced today preclinical trial results on its lead drug candidate Escozine®, a proprietary formulation consisting of small molecule peptides derived from Rhopalurus princeps scorpions, which is amplified by the Company’s polarization technology and is being researched as a treatment for various indications including the SARS-CoV-2 (COVID-19) virus and certain cancers. The preclinical trial concluded that at maximum dose levels the product is non-toxic and safe.
The study, which was completed through a third-party contract research organization (CRO) located in California under strict medical guidelines, was conducted in two phases on BALB/c mice. The first phase was completed on 12 mice where the mice were given the drug candidate at a 26 µg/kg dose volume and monitored for 24 hours. At the conclusion of the first phase, researchers did not observe any significant abnormalities. In the second phase, the same dose of the drug candidate was administered daily over the course of 14 days where researchers also observed no significant abnormalities in clinical observations, body weight, necropsy observation, hematology, and clinical chemistry. These observations rendered a study result that the candidate is well-tolerated in mice and thus is proven safe and non-toxic.
What happens when Quanta gets FDA Approval?
Selling shares for the right reasons is not a bad thing.
Bills must be paid.
The key to Quanta right now is getting Escozine FDA approved.
It will allow for the product to be used in the United States.
It would allow for doctors to write prescriptions for Escozine.
It would open the pathway for Insurance Companies to pay for these Scripts.
It would clear the way for Quanta to further submit FDA applications for other uses of ESCOZINE such as a cancer therapy.
What matters most when will the use of Escozine increase exponentially and create a runaway stock price.
The key to ALL of this is what will the response to Scorpion Venom being a solution to different medical problems.
The FDA approval process is moving right along.
We should be hearing an update the the FDA application in the coming days.
It all DEPENDS on what the Shares are being use for.
It is not like the company increase the shares and starting selling them like hot cakes.
The increase in shares and possible reverse split has legitimate and logical reasons for doing so.
Second, many of the questions submitted had to do with a recent filing we made with the SEC. I would like to provide some additional insight as to the purpose of this filing and what it could mean for the future of our company. The filing was a standard notice of two proposed corporate actions: increasing the number of shares authorized by the Company and providing authority to the Board of Directors for a potential reverse split of our shares. Regarding the first point, it is important to note that authorized and outstanding shares are different numbers. Authorized refers to the total possible shares that could be issued, and outstanding refers to the total number of shares the company has issued. Increasing the number of authorized shares did not automatically increase the number of outstanding. We increased the number of authorized shares to meet future obligations to issue shares, be able to issue shares pursuant to a future financing and to allow us to have a sufficient number of shares to make acquisitions or provide equity incentives.
Regarding the option to do a reverse split, I want to highlight that this filing gave authorization to our Board of Directors to do a reverse split in the future; it did not specify how or when we would do this. We have yet to decide if or when we would need to do this; however, again, including it in the filing now gave us yet another tool to utilize to move to a higher exchange in the future. It did not set an actual ratio that we would be held to, only a maximum allowable. We believe that having our company listed on other, more prominent exchanges, will ultimately lead to larger institutional interest and long-term shareholder value. It was imperative that we accomplish this now, while we plan for our future.
Why would a company do a reverse split with so few shares outstanding?
Why was the reverse split put in place?
Second, many of the questions submitted had to do with a recent filing we made with the SEC. I would like to provide some additional insight as to the purpose of this filing and what it could mean for the future of our company. The filing was a standard notice of two proposed corporate actions: increasing the number of shares authorized by the Company and providing authority to the Board of Directors for a potential reverse split of our shares. Regarding the first point, it is important to note that authorized and outstanding shares are different numbers. Authorized refers to the total possible shares that could be issued, and outstanding refers to the total number of shares the company has issued. Increasing the number of authorized shares did not automatically increase the number of outstanding. We increased the number of authorized shares to meet future obligations to issue shares, be able to issue shares pursuant to a future financing and to allow us to have a sufficient number of shares to make acquisitions or provide equity incentives.
Regarding the option to do a reverse split, I want to highlight that this filing gave authorization to our Board of Directors to do a reverse split in the future; it did not specify how or when we would do this. We have yet to decide if or when we would need to do this; however, again, including it in the filing now gave us yet another tool to utilize to move to a higher exchange in the future. It did not set an actual ratio that we would be held to, only a maximum allowable. We believe that having our company listed on other, more prominent exchanges, will ultimately lead to larger institutional interest and long-term shareholder value. It was imperative that we accomplish this now, while we plan for our future.
What would you like them to do?
The company needs to take of business and the it they do so successfully then that will take care of the stock price.
Quanta, Inc. (QNTA)
Highs YTD
Date Open High Low Close* Adj Close** Volume
May 17, 2021 0.1300 0.1300 0.0954 0.0990 0.0990 6,226,725
May 14, 2021 0.1390 0.1390 0.0920 0.1238 0.1238 9,964,431
May 13, 2021 0.1440 0.1680 0.1060 0.1200 0.1200 15,376,610
Apr 30, 2021 0.0700 0.2050 0.0680 0.1951 0.1951 71,773,823
Lows YTD
Apr 05, 2021 0.0485 0.0485 0.0400 0.0400 0.0400 1,619,054
Mar 30, 2021 0.0476 0.0500 0.0391 0.0398 0.0398 6,131,198
Follow the science not the STOCK PRICE
The stock price will recover when certain catalysts are released.
QNTA is going through the FDA IND application process for an unconventional and never properly peer reviewed or clinical trialed until recently.
There will be skeptics all along the way and rightly so.
Who and the hell is going to believe that Scorpion Venom is the solutions to so many medical problems.
Science is turning the tide and QNTA will once again rise.
We should be a few weeks away if not days away from an update on the latest
requirement for the FDA on the IND application.
BOOM Time soon come!!!
Are We There Yet!!!
I said NO No NO....
Best guess estimate would be 2 to 4 weeks (Prep,Test, Report) based on previous study conducted by the company:
Medolife Rx Announces Preclinical Trial Results From Toxicity Study on Lead Drug Candidate
The study, which was completed through a third-party contract research organization (CRO) located in California under strict medical guidelines, was conducted in two phases on BALB/c mice. The first phase was completed on 12 mice where the mice were given the drug candidate at a 26 µg/kg dose volume and monitored for 24 hours. At the conclusion of the first phase, researchers did not observe any significant abnormalities. In the second phase, the same dose of the drug candidate was administered daily over the course of 14 days where researchers also observed no significant abnormalities in clinical observations, body weight, necropsy observation, hematology, and clinical chemistry. These observations rendered a study result that the candidate is well-tolerated in mice and thus is proven safe and non-toxic.
The company has been tasked with measuring toxicology at DNA level:
Subsequent to the acknowledgement of the trial, the FDA has requested that the Company complete two additional toxicology studies in animals. Since adoption of COVID-19 vaccinations, the FDA altered its protocol for measuring toxicology to include studying it at the DNA level. As this is a newer development, the agency has asked Medolife to provide data in this regard. Medolife has the product and protocol necessary to complete these studies in short-order.
I have not found any information on this particular testing protocol (DNA)to suggest a time frame however I did find this on the FDA website:
The US FDA's Coronavirus Treatment Acceleration Program ...
Overview of Non-Clinical Safety Assessment for Antiviral Drugs and Vaccines Development
• To Open an IND for Small Molecule Drugs
A battery of nonclinical studies to support a first-in-human (FIH) trial should include:
- STANDARD SAFETY PHARMACOLOGY STUDIES (e.g., cardiovascular, respiratory, and central nervous system assessments) but can be incorporated into general toxicology studies
- GENERAL TOXICOLOGY STUDIES in two species (at least one nonrodent)
- GENETIC TOXICOLOGY, including an Ames reverse mutation assay and a second in vitro assessment
What is Ames reverse mutation assay?
The Ames Salmonella/microsome mutagenicity assay (Salmonella test; Ames test) is a short-term bacterial reverse mutation assay specifically designed to detect a wide range of chemical substances that can produce genetic damage that leads to gene mutations. The test employs several histidine dependent Salmonella strains each carrying different mutations in various genes in the histidine operon. These mutations act as hot spots for mutagens that cause DNA damage via different mechanisms. When the Salmonella tester strains are grown on a minimal media agar plate containing a trace of histidine, only those bacteria that revert to histidine independence (his(+)) are able to form colonies. The number of spontaneously induced revertant colonies per plate is relatively constant. However, when a mutagen is added to the plate, the number of revertant colonies per plate is increased, usually in a dose-related manner. The Ames test is used world-wide as an initial screen to determine the mutagenic potential of new chemicals and drugs. The test is also used for submission of data to regulatory agencies for registration or acceptance of many chemicals, including drugs and biocides. International guidelines have been developed for use by corporations and testing laboratories to ensure uniformity of testing procedures. This review provides historical aspects of how the Ames was developed and detailed procedures for performing the test, including the design and interpretation of results.
What does the Ames test determine?
The Ames test is a rapid and reliable bacterial assay used to evaluate a chemical's potential genotoxicity by measuring its ability to induce reverse mutations at selected loci of several bacterial strains.
What is the purpose of the Ames assay?
The Ames test is a widely employed method that uses bacteria to test whether a given chemical can cause mutations in the DNA of the test organism. More formally, it is a biological assay to assess the mutagenic potential of chemical compounds.
What is the main advantage of the Ames test for mutation detection?
The Ames test has several key advantages: It is an easy and inexpensive bacterial assay for determining the mutagenicity of any chemical. Results are robust, and the Ames test can detect suitable mutants in large populations of bacteria with high sensitivity. It does not require any special equipment or instrumentation.
How long does the Ames test take?
The plate is incubated for 48 hours. The mutagenicity of a substance is proportional to the number of colonies observed.
That being said, the testing will move the IND application forward and possibly approved if no further information is required.
Follow the science.
QNTA is going through the FDA IND application process for an unconventional and never properly peer reviewed or clinical trialed until recently.
There will be skeptics all along the way and rightly so.
Who and the hell is going to believe that Scorpion Venom is the solutions to so many medical problems.
Science is turning the tide and QNTA will once again rise.
We should be a few weeks away if not days away from an update on the latest
requirement for the FDA on the IND application.
BOOM Time soon come!!!
I don't thinks so.
QNTA be there done that.
Up and down until news hit.
Quanta, Inc. (QNTA)
Highs YTD
Date Open High Low Close* Adj Close** Volume
May 17, 2021 0.1300 0.1300 0.0954 0.0990 0.0990 6,226,725
May 14, 2021 0.1390 0.1390 0.0920 0.1238 0.1238 9,964,431
May 13, 2021 0.1440 0.1680 0.1060 0.1200 0.1200 15,376,610
Apr 30, 2021 0.0700 0.2050 0.0680 0.1951 0.1951 71,773,823
Lows YTD
Apr 05, 2021 0.0485 0.0485 0.0400 0.0400 0.0400 1,619,054
Mar 30, 2021 0.0476 0.0500 0.0391 0.0398 0.0398 6,131,198
Future of immunotherapy could be 'off-the-shelf' treatments
In a new commentary for the journal Science, an associate vice president for research at The University of Texas at Arlington argues that emerging protein-based immunotherapies could lead to highly effective "off-the-shelf" cancer treatments for more patients.
Jon Weidanz, who also is a professor in the College of Nursing and Health Innovation at UTA, is the author of a perspective regarding the development of cancer immunotherapies.
His article, "Targeting cancer with bispecific antibodies," will appear in the March 5 edition of Science. It evaluates the findings of three studies by researchers at Johns Hopkins University and proposes that an emerging method of protein-based immunotherapy that targets commonly occurring mutations in cancer cells or neoantigens -- mutated antigens produced by tumor cells -- could lead to treatments that are effective for oncology patients.
Immunotherapy, a method to treat illness by stimulating a person's immune system, is a developing alternative to traditional cancer treatments.
"Up until recently patients were limited to four treatment options: surgery, radiation, chemotherapy and targeted therapy," Weidanz said. "However, the holy grail has always been to develop strategies that would harness the power of the immune system to attack and destroy the cancer. With recent breakthroughs in immuno-oncology along with the new findings being published in Science, it does appear we are closing in on cancer with new immunotherapies."
As medicine has advanced, immunologists have discovered ways to engineer a person's T-cells, the white blood cells that fight and kill infected cells, to recognize and target cancer cells and eliminate them from the body. This approach has led to exciting advances in the field and remission in some patients. However, more work is required to make this form of T-cell therapy more broadly accessible.
Alternatively, researchers have developed approaches that stimulate the immune system without removing T-cells from the body. These "off-the-shelf" protein-based treatments, known as bispecific T-cell engaging antibodies, have proven effective in treating patients with acute lymphoblastic leukemia, a type of blood cancer.
"The ideal is to create protein molecules that have two arms. One arm can recognize the cancer cell and bind to it. The other arm binds to T-cells," Weidanz said. "The protein drug then brings the T-cells into proximity with the tumor cells, which activate the T-cells to destroy the tumor cells."
These two-armed, or bispecific, proteins would avoid healthy cells while destroying cancer cells. Weidanz argues that this method of protein-based immunotherapy could make a difference. The key comes down to the unique targets expressed by the cancer cells that the bispecific protein drug recognizes. Bispecific antibodies could bind to particular neoantigen targets found on tumor cells and recruit T-cells to destroy the cancer.
"The beauty of bispecific proteins is that you could manufacture those proteins and put them on the shelf as an immunotherapy agent," Weidanz said. "If a doctor sees that a patient's cancer expresses the neoantigen target, they could be treated immediately. It's still a personalized medicine, but would not require engineering T-cells."
An expert in immunology, Weidanz has more than 30 years of experience in biotechnology research with an emphasis on immunotherapy, especially related to oncology and product development to diagnose and treat cancer. His research lab at UTA investigates how the immune system identifies malignant cells with the goal of designing treatments that boost immune cells' ability to destroy cancerous cells.
"Dr. Weidanz's substantial expertise in the field of immunology will lead us into the next generation of cancer management," said James Grover, interim vice president of research. "The developments of his lab and those of his many talented colleagues across the nation make this a pivotal moment in the history of a devastating disease."
Weidanz said immunotherapy holds the promise of transforming cancer into a more manageable condition with better prognoses for patients.
"We are getting to a point where we will be able to make cancer more of a chronic disease," Weidanz said. "Now, we look at five-year survival. Maybe we can start looking at 15- or 20-year survival readouts because we're able to manage the disease with immunotherapies that are being developed. It's a very exciting time."
https://www.sciencedaily.com/releases/2021/03/210301171021.htm
Biopharmaceuticals deal trends: What to expect in 2021
Competition for innovation will continue to drive deal making
When the COVID-19 outbreak slammed the economy, it seemed like deal making in the biopharmaceutical industry would also slow down. However, the volume of deals hit an all-time high in 2020, with transactions using creative deal structures such as asset licensing to strategic R&D collaborations powering the growth.
A new KPMG report, Biopharmaceuticals deal trends: Competition for innovation overcomes economic headwinds, explains that the industry’s perpetual need to find innovative assets to generate future revenue will continue playing out in 2021 in the deal market. But picking the best opportunities among unproven targets amid rising valuations will be a challenge.
In this paper, we take an in-depth look at how biopharmaceutical companies are deploying their capital. We analyze what types of targets they focused on in 2020 and present our expectations for 2021. The message: For the foreseeable future, biopharma executives will continue to use a wide range of deal strategies from M&A to creative partnerships to strategic R&D collaborations to balance opportunities and risks in pursuing innovation and building their pipelines. As in the recent past, the challenge will be to select the best opportunities amid rising valuations and stillunproven targets.
Key Insights
— 2020 was a banner year—more deals than EVER!
— The total value of company acquisitions was down in 2020 compared to 2019
— The number of strategic R&D deals were up over 2X compared to prior years
— Asset licensing deals were up 233 transactions
— The number of corporate acquisitions were up in 2020 versus 2019
— Only one deal was north of $30 billion in 2020 compared to 2019 which involved two deals over $60 billion
The quest for innovation
When the COVID-19 outbreak slammed the economy, it seemed like deals in the biopharmaceutical industry and other sectors would also slow down. Many observers predicted that transaction volume would be down in 2020.
However, a deeper analysis of the industry shows that the volume of deals hit an all-time high (Exhibit 1). The total number of deals in 2020 was 1,138 compared with 634 for 2019.
The growth was particularly dramatic for transactions using creative deal structures. Strategic R&D collaborations more than doubled from 161 in 2019 to 367 in 2020. Asset licensing deals jumped from 360 to 593. In contrast, there was only one headline-grabbing mega-merger (an acquisition we define as $30 billion or more). This deal was significantly smaller than two mega-deals in 2019, both of which were for more than $60 billion.
However, there were more acquisitions under $30 billion in 2020 (121 acquisitions) versus 2019 (79 acquisitions). The total value of these was $66.8 billion (when controlling for mega-mergers), down from $70.8 billion in 2019 (Exhibit 2). This means either that deal valuations fell or the acquisitions made were on average smaller than prior years. Analyzing the deal data, we concluded that it was smaller deal size.
In the annual KPMG survey of executives across healthcare and life sciences, more than 80 percent of 31 biopharma executives surveyed said valuations had increased in 2020, and nearly a quarter estimated that values jumped by 20 percent or more (Exhibit 3).
When we asked the executives what drove valuations in 2020, a large majority (61 percent) agreed that a primary driver was intense competition for high-value and innovative assets (Exhibit 4). This perspective from the pharmaceutical executives fits both our own advisory experience and our analysis of deal data, which shows growth in deals focused on innovation (e.g. cell and gene therapies). Across the biopharmaceutical industry, companies must sustain innovation or risk significant revenue cliffs as patent protections expire. This inherent characteristic of the industry means that this acceleration of the competition for innovative assets, particularly first-inclass or second-in-class assets, will remain a major driver of the deal market.
Over the past 10 years, growth across nucleic-acid-based therapeutics—e.g. RNA, oligonucleotide, and cell and gene therapies—has outpaced even the growth in large molecule mABs. A vast number of small biotechnology companies that are pre-revenue are powering this trend.
Deals in nucleic-acid technologies were an area of significant focus for the pharmaceutical industry in 2020 (Exhibit 7). The overall deal volume across cell and gene therapies rose to 141 from 83 in 2019, largely driven by a significant growth in asset licensing deals.
Implications for 2021
We believe that companies will continue to focus on creative deals for early-stage pipeline assets in 2021 and beyond, as companies seek to mitigate the risk of investing in early-stage assets. According to our survey, pharma will be:
— Early-stage, pre-revenue biotech acquisitions;
— Strategic partnerships; and
— Creative equity or financing deals with milestones.
Conclusion: Position to win
The competition for innovation pushes biopharmaceutical companies to
pursue earlier-stage pipeline assets in order companies to pursue earlier-stage pipeline assets in order compounded by the fact that these early-stage assets have lower probabilities of success, and many of the different emerging technologies are competing with each other for the same future commercial opportunities.
Predicting which technology will succeed or displace other emerging innovations is a gamble—the range of disruptive technologies in the global pharmaceutical pipeline is too diverse and it’s too early to know which will succeed. This is driving many savvy pharmaceutical and biotech companies to spread their bets and invest across multiple modalities.
We also expect more deals using creative structures focused on milestone-based investments in clinical-stage assets and increasingly, on pre-clinical-stage ones. The fight for innovation is now a battle for rights to own a wider range of platforms and individual assets that are early in development.
For Full Article Click on Link:
https://advisory.kpmg.us/content/dam/advisory/en/pdfs/2021/biopharmaceuticals-deal-trends.pdf
Why scorpion venom is the most expensive liquid in the world
Scorpion venom is not only dangerous — it can also make you quite a bit of money.
The deathstalker is one of the most dangerous scorpions on the planet, and its venom is also the most expensive liquid in the world at $39 million per gallon.
But it's not so simple to just buy a gallon — you'd have to milk one scorpion 2.64 million times to fill a gallon.
Following is a transcript from the video:
Narrator: The deathstalker is one of the most dangerous scorpions on the planet, and what makes it so dangerous also happens to be the most expensive liquid in the world. This stuff costs $39 million per gallon. Now, even if you had the money, you couldn't just go and buy a gallon of the stuff, because you can only get it in tiny, minuscule amounts. $130 will get you a droplet that's smaller than a grain of sugar.
The reason why is pretty simple: the stuff is hard to get. Scorpions are almost always milked by hand, one by one. And one scorpion produces, at the most, just two milligrams of venom at a time.
So, let's do the math. If you owned one scorpion you would have to milk it 2.64 million times to fill a gallon. And let's face it, you'd probably get stung along the way as well. One sting isn't enough to kill a healthy human, but I think it hurts.
Steve Trim: I'd easily put it being a hundred times more painful than a bee sting, but because pain is a subjective and emotional experience, it's difficult to really get a quantification on that. But it's definitely gonna ruin your day.
Narrator: That's Venomtech founder Steve Trim, one of the few people brave enough to deal with these animals. That's because inside that deadly venom, there's actually tons of useful components that are helping pioneer breakthrough medicines.
Chlorotoxins, for example, are the perfect size to bind with certain cancer cells in the brain and spine, which is helpful for identifying the specific size and location of tumors. And researchers have used scorpion to eliminate malaria in mosquitoes. Kaliotoxin has been given to rats to fight bone disease. Scientists hope it could work in humans too.
These are just a few of the medical benefits that researchers have found in scorpion venom. And the more they research it, the more uses they find. Which means demand for this miracle venom continues to grow. So scientists are now trying to figure out ways to get more of it faster.
Like this group out of Morocco, who invented the first remote control machine for milking scorpions. It can safely milk up to four scorpions at a time. It might not sound like much, but it's four times faster than a human. Scientists hope to get on the market within a few years, making the whole process faster and safer.
"Faster and safer?", you're probably thinking, "Hmmm, maybe I should start my own scorpion farm."
Well, get in line, wise guy.
Steve Trim: There clearly has been a surge in people thinking, "Oh, this is a get rich quick scheme." But with people not understanding how scorpion venom is used. We have seen a rise in the number of people saying they've got 300 grams of scorpion venom, do we want to buy it? And the answer is "No, we've got our own."
EDITOR'S NOTE: This video was originally published in August 2018.
https://www.businessinsider.com/scorpion-venom-most-expensive-liquid-in-the-world-2018-8
Somebody told somebody else about RGBP and then they told somebody else who did what?
Yes you got it they told somebody else and the question is how many somebodies knows something?
It really doesn't matter because whatever they know:
1. They like it
2. They believe it
3. They are investing in it
Whoever they are they are investing tens of thousands of dollars on a Friday afternoon.
Something has hatched
Quanta, Inc. (QNTA)
Highs YTD
Date Open High Low Close* Adj Close** Volume
May 17, 2021 0.1300 0.1300 0.0954 0.0990 0.0990 6,226,725
May 14, 2021 0.1390 0.1390 0.0920 0.1238 0.1238 9,964,431
May 13, 2021 0.1440 0.1680 0.1060 0.1200 0.1200 15,376,610
Apr 30, 2021 0.0700 0.2050 0.0680 0.1951 0.1951 71,773,823
Lows YTD
Apr 05, 2021 0.0485 0.0485 0.0400 0.0400 0.0400 1,619,054
Mar 30, 2021 0.0476 0.0500 0.0391 0.0398 0.0398 6,131,198